Anuh Pharma Q2 FY27 Results & Earnings Intelligence
ANUHPHRStructural risk assessment following Q2-FY27 | 30 Sep 26 earnings.
₹185.2 Cr
-4.4% QoQ
₹15.0 Cr
+51.7% YoY•-11.1% QoQ
₹11.2 Cr
+47.3% YoY•-1.9% QoQ
35/ 100
+16 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q2-FY27 | 30 Sep 26 | Q2-FY26 | 30 Sep 25 | YoY Δ | Q1-FY27 | 30 Jun 26 | QoQ Δ |
|---|---|---|---|---|---|
| Revenue from Operations | ₹185.2 Cr | N/A | N/A | ₹193.8 Cr | -4.4% |
| Revenue (Total Income) | ₹185.8 Cr | ₹186.9 Cr | -0.5% | ₹196.9 Cr | -5.6% |
| Operating Profit (EBITDA) | ₹15.0 Cr | ₹9.9 Cr | +51.7% | ₹16.9 Cr | -11.1% |
| Profit Before Tax (PBT) | ₹15.0 Cr | ₹9.9 Cr | +51.7% | ₹16.9 Cr | -11.1% |
| EBIT Margin | 8.10% | 5.31% | +279 bps | 8.60% | -50 bps |
| Net Profit (PAT) | ₹11.2 Cr | ₹7.6 Cr | +47.3% | ₹11.4 Cr | -1.9% |
| Interest Expense | ₹0.1 Cr | ₹0.1 Cr | -31.5% | ₹0.0 Cr | +1380.0% |
| Operating Cash Flow | ₹26.7 Cr | ₹-26.8 Cr | +199.6% | N/A | N/A |
| Basic EPS (₹/share) | ₹1.12 | N/A | N/A | ₹1.14 | -1.8% |
Sources:Official BSE/NSE Disclosures & Financial Filings
Core operating EBITDA margin of 8.1% reflects operating leverage, gross spread absorption, and input cost discipline against revenue.
Sentinel Executive Summary
Core Earnings Synthesis"Anuh Pharma Limited currently sits within Flagium's Watch category. However, recent periods have introduced early signs of competitive and operating pressure. While profitability was defended, revenue contraction and triggers like 'Universal Inventory Divergence', 'Inventory Stress' increased structural risk. While not currently existential, persistent friction suggests that structural risk is rising."
Anuh Pharma Limited registered a drop in both quarterly revenue and net profit, reflecting challenging industry-wide demand trends. A 'Watch' risk classification and 3 active flags indicate that operating headwinds are beginning to translate into structural pressure.
🟢 Key Operational & Structural Positives
- ✓Net Profit Expansion: Profit after tax moved +47.3% YoY and -1.9% QoQ, settling at ₹11.2 Cr.
- ✓Operating Margins: Operating margin moved +279 bps YoY and -50 bps QoQ to 8.10%.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Resolution of 'Universal Inventory Divergence': ANUHPHR: YoY Inventory growth (+45.9%) outpaced Revenue growth (-0.5%) by +46.4 pp (Inventory holding ratio increased +46.7%).
- ⚠Resolution of 'Inventory Stress': Inventory growth (45.9%) significantly outpaced revenue growth (-0.5%).
- ⚠Resolution of 'Industrial Margin Stress': ANUHPHR: Raw material costs consumed an additional 5.9% of revenue YoY.
Net Profit (PAT) grew +47.3% YoY, but declined -1.9% QoQ vs Q1-FY27, reflecting sequential quarter-end variability.
Flagium Risk Signals
Automated Forensic SignalsUniversal Inventory Divergence • Inventory Stress • Industrial Margin Stress
ANUHPHR: YoY Inventory growth (+45.9%) outpaced Revenue growth (-0.5%) by +46.4 pp (Inventory holding ratio increased +46.7%).
Inventory growth (45.9%) significantly outpaced revenue growth (-0.5%).
ANUHPHR: Raw material costs consumed an additional 5.9% of revenue YoY.
🎙️ Anuh Pharma (ANUHPHR) Q2 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
No earnings call transcript was available
for this reporting period.
What to do next
Explore ANUHPHR's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View ANUHPHR profile →See how Healthcare peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q2-FY27 | 30 Sep 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
📬 Flagium Risk Brief — Track forensic risks on ANUHPHR & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.